In 2021, antalgic drugs represented a market of 71,3 billion dollars. An average increase of 3,92% is expected between 2022 and 2030.
TAFALGIE THERAPEUTICS is a simplified joint-stock biotechnology company, Spin-off of the IBDM laboratory (AMU/CNRS).
The society is created IN OCTOBER 2020 BY FOUR FOUNDERS having complementary and internationally recognized expertise in the fields of neurosciences, research, finances and industrial development.
Réalisé avec ❤️